Trial Profile
A Randomised Trial Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 07 Nov 2018 Results of a post hoc analysis of NCT01618188, NCT02003677, NCT01934712, NCT02568280 and NCT01831765 assessing the PK of fast-acting Insulin Aspart versus free Insulin Aspart, published in the Clinical Pharmacokinetics
- 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation.
- 29 Apr 2016 Status changed from active, no longer recruiting to completed.